It has been recently shown that COVID-19 is associated with a clinically significant coagulopathy. Several studies have indicated that elevated markers of fibrin degradation (D-dimers) in hospitalised patients are associated with poorer prognosis (death or ICU admission) (Fogarty et al., 2020, Connors and Levy, 2020). Coagulation test screening is suggested and routine thromboprophylaxis measures (including use of low molecular weight heparin) are recommended, although full anticoagulation is not yet advised in the management of such patients unless otherwise clinically indicated (Connors and Levy, 2020). We wish to draw attention to a potentially enhanced risk of thromboembolic complications in patients with psychotic disorders.

中文翻译：

---

COVID-19、高凝状态及其对精神障碍患者的意义


最近的研究表明，COVID-19 与临床上显着的凝血病有关。多项研究表明，住院患者的纤维蛋白降解标记物（D-二聚体）升高与预后较差（死亡或入住 ICU）相关（Fogarty 等人，2020；Connors 和 Levy，2020）。建议进行凝血测试筛查，并建议进行常规血栓预防措施（包括使用低分子量肝素），但除非有其他临床指征，否则尚不建议在此类患者的治疗中进行全面抗凝（Connors 和 Levy，2020）。我们希望提请注意精神障碍患者发生血栓栓塞并发症的潜在风险增加。